Research programme: small activating RNA therapeutics - MiNA Therapeutics

Drug Profile

Research programme: small activating RNA therapeutics - MiNA Therapeutics

Alternative Names: RNAa - Mina Therapeutics; saRNA - MiNA Therapeutics

Latest Information Update: 06 Nov 2015

Price : $50

At a glance

  • Originator MiNA Therapeutics; University of California at San Francisco; University of Texas Southwestern Medical Center
  • Developer Marina Biotech; MiNA Therapeutics
  • Class RNA
  • Mechanism of Action RNA stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Liver cancer

Most Recent Events

  • 03 Nov 2015 Marina Biotech has patent protection for SMARTICLES® delivery technology and for the composition of NOV 340 in Canada
  • 01 Dec 2014 MiNA Therapeutics receives patent allowance for saRNA therapeutics in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top